ERVW-1 and HIV-1 infection: Data from the RV144 clinical vaccine trial demonstrated that a reduced risk of HIV-1 infection correlated with binding titer of IgG3 antibodies to HIV Env variable regions 1 and 2 (V1/V2), reinforcing the role of Env-specific antibodies in preventing infection [7].